Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levonorgestrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 8/20 | 1.00 |
| ▸ | AR | P10275 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | ESR1 | P03372 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 4/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | SHBG | P04278 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.71 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levonorgestrel SCHEMBL3916570 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL14360765 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL27597 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL691861 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Norgestrel SCHEMBL37118 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Norgestrel SCHEMBL4319113 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL22364344 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL21741985 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL20927506 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 | |
| Levonorgestrel SCHEMBL11697371 | 1.00 | PGR (1.00) | PGRARLMNACYP3A4SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096855-A1 | Process for obtaining norelgestromin in different relations of isomers E and Z | TOMBARI DORA G | 2008-04-24 | — | — | US | claimed |
| EP-0904086-B1 | TRANSDERMAL SYSTEMS CONTAINING TWO ACTIVE PRINCIPLES IN SEPARATE COMPARTMENTS, THEIR METHOD OF PREPARATION AND APPLICATION AS MEDICINE | AVENTIS PHARMA SA (FR) | 2004-12-08 | — | — | EP | claimed |
| US-20240238310-A1 | MODULATION OF SEX STEROID HORMONE PRODUCTION AND ACTIVITY FOR TREATING AND PREVENTING HERNIAS | NORTHWESTERN UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| CN-117715644-A | Pure progestogen oral contraception | 纳瓦达生命科学公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20230414618-A1 | Methods of Administering Elagolix | ABBVIE INC (US) | 2023-12-28 | — | — | US | disclosed |
| US-20230285414-A1 | PROGESTOGEN-ONLY ORAL CONTRACEPTION | Navad Life Sciences Pte (SG) | 2023-09-14 | — | — | US | disclosed |
| US-11679114-B2 | Progestogen-only oral contraception | Navad Life Sciences Pte (SG) | 2023-06-20 | — | — | US | disclosed |
| US-20230172947-A1 | METHODS AND COMPOSITIONS FOR TREATING ENDOMETRIAL CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-06-08 | — | — | US | disclosed |
| US-20230036801-A1 | PROGESTOGEN-ONLY ORAL CONTRACEPTION | Navad Life Sciences Pte (SG) | 2023-02-02 | — | — | US | disclosed |
| US-20210283144-A1 | MODULATION OF SEX STEROID HORMONE PRODUCTION AND ACTIVITY FOR TREATING AND PREVENTING HERNIAS | NORTHWESTERN UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
| US-20120129825-A1 | METHOD FOR ON-DEMAND CONTRACEPTION USING LEVONORGESTREL OR NORGESTREL | FAMILY HEALTH INTERNATIONAL | 2012-05-24 | — | — | US | disclosed |
| EP-0253607-B2 | Combination dosage form for premenopausal women | AMERICAN HOME PROD (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-0904086-A1 | TRANSDERMAL SYSTEMS CONTAINING TWO ACTIVE PRINCIPLES IN SEPARATE COMPARTMENTS, THEIR METHOD OF PREPARATION AND APPLICATION AS MEDICINE | HOECHST MARION ROUSSEL (FR) | 1999-03-31 | — | — | EP | disclosed |
| WO-1997047305-A1 | TRANSDERMAL SYSTEMS CONTAINING TWO ACTIVE PRINCIPLES IN SEPARATE COMPARTMENTS, THEIR METHOD OF PREPARATION AND APPLICATION AS MEDICINE | HOECHST MARION ROUSSEL (FR) | 1997-12-18 | — | — | WO | disclosed |
| US-5478571-A | Solubilizing hormones, steroids or oral contraceptives to alcoholic solvents, mixing a carrier, removing solvent by evaporation, adding water, tabellation or encapsulation | WARNER-LAMBERT COMPANY (US) | 1995-12-26 | — | — | US | disclosed |
| WO-1994018951-A1 | A PROCESS FOR THE PREPARATION OF SUBSTANTIALLY ALCOHOL FREE PHARMACEUTICAL COMPOSITIONS | WARNER-LAMBERT COMPANY (US) | 1994-09-01 | — | — | WO | disclosed |
| EP-0253607-B1 | COMBINATION DOSAGE FORM FOR PREMENOPAUSAL WOMEN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-04-29 | — | — | EP | disclosed |
| WO-1988000469-A1 | COMBINATION DOSAGE FORM FOR PRE-MENOPAUSAL WOMEN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-01-28 | — | — | WO | disclosed |
| EP-0253607-A1 | Combination dosage form for premenopausal women | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-01-20 | — | — | EP | disclosed |
| US-RE28690-E | OVULATION INHIBITION | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172947-A1 | METHODS AND COMPOSITIONS FOR TREATING ENDOMETRIAL CANCER | HSD17B11, CYP19A1, NR5A1 | PGR 5/4885AR 91/4885LMNA 579/4885 |
| US-20230414618-A1 | Methods of Administering Elagolix | CYP2D6, CYP19A1, CYP2B6 | PGR 33/4885AR 258/4885LMNA 3351/4885 |
| US-20080096855-A1 | Process for obtaining norelgestromin in different relations of isomers E and Z | CYP19A1, HSD17B11, CYP17A1 | PGR 61/4885AR 247/4885LMNA 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.